-

Incyte Investor Conference Update

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) has updated its presentation time at the following investor conference:

  • JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT).

The presentation at the BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 p.m. (EDT) is unchanged.

The presentations for both conferences will be webcast live and can be accessed at Investor.Incyte.com. Replays will be available for 30 days.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Media
Catalina Loveman, +1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Summary
Incyte Investor Conference Update.
Release Versions
English
$Cashtags
$INCY

Contacts

Media
Catalina Loveman, +1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com

Social Media Profiles
Incyte Corporation
More News From Incyte

Incyte Announces Change to its Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Change to its Board of Directors...

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET...

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025...
Back to Newsroom